Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Genmab A/S (NASDAQ:GMAB) has been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $45.20.

Several equities analysts have recently issued reports on GMAB shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th.

Institutional Trading of Genmab A/S

Hedge funds have recently made changes to their positions in the company. Lindbrook Capital LLC grew its holdings in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC increased its position in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Cromwell Holdings LLC raised its position in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares in the last quarter. R Squared Ltd bought a new position in shares of Genmab A/S in the 4th quarter worth about $93,000. Finally, Blue Trust Inc. raised its stake in Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after acquiring an additional 3,880 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Down 1.8 %

NASDAQ GMAB opened at $19.00 on Friday. Genmab A/S has a 1-year low of $18.92 and a 1-year high of $31.88. The company has a market capitalization of $12.57 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 0.55 and a beta of 0.96. The stock’s 50 day moving average is $20.89 and its two-hundred day moving average is $23.49.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the prior year, the firm posted $0.47 earnings per share. On average, analysts predict that Genmab A/S will post 1.25 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.